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Summary High body weight is associated with increased production of oestrogens which may influence the
clinical behaviour of breast cancer. We have examined the influence of body weight on the response to
endocrine therapy, steroid hormone receptor content and survival in 227 women who either presented with or
developed advanced cancer of the breast. One hundred and thirty-three (59%) patients presented with
operable disease and 94 (41%) with locally advanced tumours. Two hundred (88%) were treated by tamoxifen
and 27 (12%) by ovarian ablation.
High body weight was correlated with advanced tumour stage (P=0.002) and progesterone receptor (PR)
positivity (P=0.01), but not with the presence of oestrogen receptor (ER P=0.21). The association between
high body weight and PR positivity was particularly noticeable among ER positive tumours. There was no
significant relationship between the nature of the response to therapy and weight (P=0.57). There was no
significant difference in survival from the start of endocrine therapy (P=0.95), nor the time to progression of
disease (P=0.29) between patients above and below the median weight of 64kg. Among the patients with
operable disease, there was no difference in overall survival (P=0.42), relapse free survival (P=0.69), and
survival from the start of endocrine therapy (P=0.85) according to body weight.
Most epidemiological evidence suggests that high body
weight and obesity are correlated with the incidence of
breast cancer, particularly in postmenopausal women
(Dewaard, 1982). Furthermore, these factors are generally
associated with a worse prognosis (Papatestas et al., 1986;
Abe et al., 1976; Eberlein et al., 1985; Greenberg et al., 1985;
Donegan et al., 1978; Tartter et al., 1981; Newman et al.,
1986; Boyd et al., 1981), although one small study did not
confirm this effect (Sohrabi et al., 1980). Similarly in mice,
obesity and a fat enriched diet increase the incidence and
speed of onset of mammary tumours (Waxler et al., 1979).
In postmenopausal women the major source of oestrogens
is the conversion of androstenedione, derived from the
adrenal gland, to oestrone in body fat by the aromatase
system (Cloncope, 1971; MacDonald et al., 1969). The
strong correlation between the production of oestrone, the
degree of this conversion and indices of obesity (e.g., weight,
percentage of ideal weight and weight:height ratio) suggests
that the excess production of steroid hormones within body
fat which promotes the growth of mammary epithelial cells,
may be the mechanism whereby there is an association
between body weight and tumour incidence (Rizkallah et al.,
1975; McDonald et al., 1978; Kirschner et al., 1982). This is
supported by the report of lower levels of sex hormone
binding globulin in the obese which may lead to higher levels
of free oestrogens (Kirschner et al., 1982).
Our working hypothesis for this study was that the greater
endogenous production of growth promoting steroids in
women of above average weight might override the effects of
endocrine treatment and lead to a lower response rate and
reduced survival in this group. We have therefore studied a
group of 227 patients who developed advanced, evaluable
cancer of the breast, all of whom were treated either with
tamoxifen, or by ovarian ablation.
Patients and methods
Patients
Between November 1975 and December 1983, 670 patients
with advanced cancer of the breast were treated at this
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centre. Four hundred and twenty-nine of these received
endocrine therapy as first systemic treatment after relapse.
This was either by ovarian ablation or with tamoxifen in
393. Of this group 115 cases were excluded because they
were not assessable for response, 15 because they had had
adjuvant endocrine therapy and 36 because details of their
weight were not available. This left 227 patients for study
and their details are given in Table I. One hundred and
thirty-three of 227 (59%) presented with operable disease
and 94/227 (41%) with locally advanced disease. Twenty-
seven (12%) were treated by ovarian irradiation or oophor-
ectomy and 200 (88%) by tamoxifen. The details of the
patients at the start of endocrine treatment are given in
Table II.
All were assessable for response by UICC criteria
(Hayward et al., 1977). Tumour oestrogen and progesterone
receptors were analysed as previously described (Harland et
al., 1983; Barnes et al., 1977).
Statistical methods
Survival curves were calculated by the Kaplan-Meier
method and compared by the log-rank test (Peto et al.,
1977). Body weight as a continuous variable and other
factors of potential prognostic importance (recorded in
Tables I and II) were included in a multivariate analysis
using the Cox proportional hazards model (Cox, 1972). The
distribution of body weight in relation to several patient and
tumour variables and response to treatment was investigated
by one-way analysis of variance. Pairwise comparisons were
made when a significant difference was found using Scheffe's
Test. Body weight at the start of endocrine therapy was
related to response, time to progression and survival from
the start of therapy. Body weight at presentation was used
for the other analyses.
Results
The median weight of the patients was 64kg. There was no
significant difference in the survival of the whole group from
the start of endocrine therapy, between patients who were
above or below the median weight (P=0.95, Figure la).
There was also no difference in the time to progression of
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a Table I Characteristics of patients at presentation (n=227)
n %
Age
T-stage
N-stage
<50
50+
TO
TI
T2
T3
T4
unknown
NO
NI
N2
N3
unknown
53 (23)
174 (77)
3
15
98
32
74
S
107
80
22
16
2
(1)
(7)
(43)
(14)
(33)
(2)
(47)
(35)
(10)
(7)
(1)
Operable n= 133 133 (59)
+ 115
- 53
unknown 59
+ 84
- 82
unknown 61
(51) If value at
(23) presentation not
(26) known then the value
at relapse is quoted,
(37) if this was also not
(36) known then value at
(27) start of endocrine
treatment is given
Table II Characteristics of patients at start of endocrine treatment
n %
Previous adjuvant chemotherapy No 194 (85)
Yes 33 (15)
Number of relapses 1 174 (77)
2 44 (19)
3+ 9 (4)
Age <50 41 (18)
50+ 186 (82)
Menopausal status PRE 34 (15)
PERI 9 (4)
POST 168 (74)
Unknown 16 (7)
Karnofsky performance status <50 5 (2)
60 7 (3)
70 35 (15)
80 55 (24)
90 108 (48)
Unknown 17 (8)
Dominant site of disease Soft tissue 68 (30)
Bone 72 (32)
Lung 50 (22)
Liver 15 (6)
Other 22 (10)
Number of major sites 1 100 (44)
2 74 (33)
3+ 53 (23)
Type of treatment Ovarian ablation 27 (12)
Tamoxifen 200 (88)
disease between the two groups (P =0.29, Figure b).
Amongst those patients who presented with operable disease
(n= 133), there were no significant differences in overall
survival (P=0.42), relapse-free survival (P=0.69, Figure lc),
or survival from the start of endocrine therapy (P=0.85),
between those patients who were above or below the median
weight. Menopausal status did not affect these results.
There was also no relationship between the time to
progression and survival between the two groups when
individual response categories (i.e., complete and partial
response, no change and progressive disease) or individual
receptor categories (i.e., ER+, ER-, PR+, PR-) were
considered.
All the above analyses were repeated after dividing
patients into three groups by weight (<60kg, 60-70kg and
>70kg) and similar results were found.
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Figure 1 (a) Survival from the start of endocrine therapy
(n=227); (b) Time to progression of disease (n=227); (c)
Relapse-free survival of patients who presented with operable
disease (n=133).
The distribution of body weight was unrelated to the age
of the patient, menopausal status, histology of the tumour,
axillary node status and the nature of the response to
endocrine therapy (Table III). There was however, a signifi-
cant association between body weight and the stage of the
tumour at presentation (P=0.002, Table III).
There was no significant relationship between body weight
and the ER status of the primary tumour and this held true
when the first time of measurement was considered, i.e.,
either on presentation, or first relapse, or at the start of
endocrine treatment (Table IV). However, an association was
noted between high body weight and PR positivity which
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Table III Response to endocrine treatment and T-stage in
relation to body weight
Mean body
weight at
endocrine
treatment
(kg)
Progressive disease n= 106 64.9
No change n= 51 64.8 P=0.64
Partial response n= 52 64.9
Complete response n= 18 68.6
Mean body
weight at
presentation
(kg)
Ti n= 10 54.6
T2 n= 94 63.2 p=0.002 T3 n= 30 64.4 P=02
T4 n= 73 67.9
Weight at presentation was unknown in 20 patients, but
was recorded in all patients at the start of endocrine
treatment.
Table IV Receptor status in relation to body
weight at presentation
Mean
Number of weight
patients (kg) P value
Primary tumour
ER+ 95 66.0 0.47
ER- 39 64.4
PR+ 68 67.9 0.07
PR- 65 64.1
First recorded measurement
ER+ 112 66.4 0.21
ER- 50 63.9
PR+ 82 68.1 0.010
PR- 79 63.4
Primary tumour
ER- PR- 34 65.7
ER+ PR- 30 61.4 0.028
ER+ PR+ 64 68.2
First recorded measurement
ER- PR- 43 64.7
ER+ PR- 36 61.8 0.010
ER+ PR+ 75 68.6
reached statistical significance for the first recorded measure-
ment. Furthermore, when the combined receptor status of
each tumour was considered, significant differences were seen
in terms of body weight. This revealed a higher mean body
weight for ER +PR + patients compared with ER + PR-
patients. The number of patients in the ER-PR+ category
was too small for analysis.
A multivariate analysis for all variables of possible impor-
tance showed that the only indicators of prognosis were the
response to therapy (P<0.000001) and Karnofsky perform-
ance status (P=0.0007). Body weight was of no significance.
ER and PR emerged as significant prognostic factors in
univariate analysis. In the multivariate analysis, however,
when response to therapy was included, ER and PR were no
longer significant and a strong correlation between both ER
and PR and response to therapy (P<0.002) was found.
Discussion
We were surprised to find that body weight was unrelated to
survival and response to endocrine therapy in this group of
patients who either developed or presented with advanced
breast cancer.
Several studies have reported an association between high
body weight and axillary lymph node involvement (Abe et
al., 1976; Eberlein et al., 1985; Greenberg et al., 1985; De
Waard et al., 1977). In some of these there was also an
association between high body weight and reduced disease
free and overall survival (Abe et al., 1976; Eberlein et al.,
1985; Greenberg et al., 1985). Patients above the median
weight are more likely to be obese and to have large breasts
where small tumours are more difficult to detect than in
small breasts and it is well described that the larger the
tumour the more likely axillary nodes are to be involved.
The reported reduced survival of obese patients may be due
to relatively late presentation, however, in some studies the
adverse effect of obesity persisted after adjustment for
tumour size and axillary node status (Greenberg et al., 1985;
Tartter et al., 1981; Boyd et al., 1981). There was a
significant association between high body weight and tumour
stage in this study. However, in patients who will relapse, or
who present with locally advanced disease, node status and
tumour size are relatively unimportant indicators of progno-
sis. They are most important for the determination of the
probability of the presence of metastatic disease which is not
relevant to the series presented here since all patients pre-
sented with or developed advanced breast cancer.
In one study of adjuvant endocrine therapy in 749 patients
(Boyd et al., 1981), the overall disease-free survival of
women who weighed >64kg was significantly less than that
of those who weighed <64kg. Among the premenopausal
women aged >45 years, who weighed >64kg, there was a
significantly longer disease-free survival among those women
who received adjuvant endocrine therapy compared to those
who received no treatment. This effect was not seen in those
who weighed <64kg which suggests that in this selected
group of women, those of above average weight are more
likely to respond to endocrine therapy.
However, in the group of patients with advanced disease
in our study there was no relationship between body weight
and the probability of response to endocrine therapy.
In the multivariate analysis for factors which affect survi-
val from the start of endocrine therapy, response was of
overriding importance. There was no association between
body weight and the ER content of the tumour which is in
agreement with one study (Eberlein et al., 1985) but not
another in which a higher incidence of ER -ve tumours in
heavier patients was reported (Papatestas et al., 1986). For
ER positive tumours, PR is significantly more likely to be
present among heavier women, which is consistent with the
fact that oestrogen may combine with its receptor to induce
PR.
There was a significant correlation between high body
weight and PR positivity and the ER+PR+ combination,
which confer a higher likelihood of response to endocrine
therapy (Adami et al., 1984). No relationship was established
between weight and response. However, the patients who
had a complete response were heavier than those in other
categories of response and it is conceivable that with more
patients, this difference would have reached significance.
Our original hypothesis was that women of above average
weight would have a worse response because their greater
production of endogenous hormones might stimulate tumour
cell proliferation in receptor-positive tumours and override
the inhibitory effects of ovarian ablation or the use of
tamoxifen. Owing to the relatively small numbers of patients
in this study, we cannot exclude a small effect of weight on
response to therapy, but if an effect is present it is likely to
be of theoretical rather than of clinical importance.634 G. WILLIAMS el al.
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